[Current therapy of prostate carcinoma]

Despite the high incidence and the intensive research, the appropriate diagnostic and therapeutic approach for prostatic carcinoma (PCA) is still controversial. PSA and its new subtests allow earlier diagnosis of PCA. No rigid guidelines can be given concerning therapy. The therapeutic regimen has always to be adapted to the patient's individual needs and situation. For organ-confined and progressive disease, new concepts have been introduced. They seem to improve quality of life rather than to achieve prolonged survival.